New Study Finds Antimicrobial Resistance Now A Leading Cause Of Death Worldwide

A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections. 

New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections.

According to the paper’s co-author Prof Chris Murray:

“These new data reveal the true scale of antimicrobial resistance worldwide, and are a clear signal that we must act now to combat the threat.”

Twelve months ago, Botanix published important research data in collaboration with the University of Queensland showing the ability of synthetic CBD to kill a select group of Gram-negative bacteria, and highlighting the potential of CBD as the foundation of a new class of antimicrobials.

Read the article in The Guardian

Edison Open House Video

Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the  2022 Edison Open House: Global Healthcare virtual event this week.

He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:

“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”

2022 Edison Open House: Global Healthcare

Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.

Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.

Click here to register, it’s free.

Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.

Click here to read the report.

AGM Presentation

Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA.

To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology and infection control.

Click here to review presentation.

4th International Cannabinoid Derived Pharmaceuticals Summit

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

Atopic Dermatitis Update + Presentation

Botanix Pharmaceuticals has today updated the market with plans for its Atopic Dermatitis (AD) clinical program. This follows important recent learnings on drug dose and formulation design of synthetic CBD in dermatitis applications, together with positive data from a new pilot study conducted in canines with AD.

Canine atopic dermatitis is clinically and immunologically similar to human AD, providing an efficient approach to inform progression of further human studies too.

A recent pilot study of Botanix’s BTX 1204A product in canines (a new higher dose formulation of synthetic CBD for atopic dermatitis, leveraging PermetrexTM), demonstrated significant reductions on average in both the Enhanced Pruritus Score (ESP) and Canine Atopic Dermatitis Extent and Severity Index (CADESI-04) scores over the 28-day treatment period.

Botanix is now advancing plans for a larger BTX 1204A proof of concept canine study in Australia, with goals to confirm and expand safety and efficacy data. Following this, the Company will pursue opportunities for partnering the product in animal health markets and progress towards a Phase 2b study for AD in humans in 1H 2022.

Read today’s ASX release and presentation here.

Investor Conference Call

Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, and Executive Director, Matt Callahan, hosted an investor conference call on Friday 7 May 2021.

You may listen to the audio file here:

Ticker News Interview

Botanix Pharmaceutical’s (ASX:BOT) Executive Director, Matt Callahan, spoke with the Ticker News team yesterday to detail the next phase of our BTX 1801 antimicrobial program, which will target nasal decolonisation of Staph aureus in haemodialysis patients.

Investor Presentation + Conference Call

Botanix Pharmaceuticals has today released an updated investor presentation and registration details for a conference call with our investors and supporters.

participants can pre-submit questions to be answered at the end of the call, when registering through the link below.

See the updated investor presentation here.

Conference call details:

Date: Friday, 7 May 2021

Time: 11:00am AEST

Registration details:

Participants are encouraged to pre-register for the conference call. Upon registration, participants will receive a unique pin granting fast-track access to the conference call and the opportunity to submit questions to our team.

Register now.

BTX 1801 Clinical Development Update

Botanix Pharmaceuticals has today released a comprehensive update and presentation on imminent plans for the BTX 1801 antimicrobial platform program.

The next phase of development for BTX 1801 will focus on targeting the nasal decolonisation of Staph aureus in haemodialysis patients, which represents a significant market opportunity to prevent bloodstream infections in these patients.

Dialysis largely replicates the functions of the kidneys in patients with chronic kidney failure, with dialysis taking over the key functions of the kidneys (including filtering and removing waste materials from the body).  Haemodialysis patients undergoing ongoing dialysis regularly (e.g. three to five times per week), are at a high risk of bloodstream infections, due to their treatment requiring frequent use of catheters which in the first year are routinely central lines with direct access to the heart.

Our team is energised by the opportunity to develop a novel approach for removing sources of bacteria to prevent bloodstream infections in haemodialysis patients – which is desperately needed. Our prior work to examine the unique bactericidal mechanism of action of synthetic cannabidiol provides great confidence for this program too.

Read today’s ASX release and presentation here.